There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Amarin (NASDAQ:AMRN) and Immutep Limited (Other OTC:IMMP) with bullish sentiments.
Amarin (AMRN)
In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Amarin, with a price target of $10. The company’s shares closed on Friday at $2.99.
Chen commented:
“We think the peak sales potential of Vascepa is under appreciated. Therefore, upwards earnings revisions to levels not reflected in consensus should drive AMRN shares higher. Valuation Summary We continue to use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $10.”
According to TipRanks.com, Chen is ranked 0 out of 5 stars with an average return of -10.2% and a 37.2% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Melinta Therapeutics Inc.
Currently, the analyst consensus on Amarin is a Moderate Buy with an average price target of $10.
See today’s analyst top recommended stocks >>
Immutep Limited (IMMP)
In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Immutep Limited, with a price target of $7. The company’s shares closed on Friday at $3.01, close to its 52-week high of $3.36.
McCarthy noted:
“Immutep announced it has entered into a clinical trial collaboration and supply agreement with Merck KGaA (MRK.DE – NR) and Pfizer (PFE – NR) to evaluate the company’s lead asset eftilagimod (LAG-3, IMP321) alpha with PD- L1 inhibitor avelumab in solid tumors.”
According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 15.5% and a 49.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
Immutep Limited has an analyst consensus of Moderate Buy, with a price target consensus of $7.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
